Akero Therapeutics, Inc. $AKRO Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 148.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,391 shares of the company’s stock after purchasing an additional 1,429 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Akero Therapeutics were worth $128,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AKRO. KBC Group NV acquired a new stake in Akero Therapeutics during the 1st quarter worth approximately $120,000. Amalgamated Bank increased its position in Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after purchasing an additional 410 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Akero Therapeutics during the 1st quarter worth approximately $10,404,000. Bank of New York Mellon Corp increased its position in Akero Therapeutics by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 212,665 shares of the company’s stock worth $8,609,000 after purchasing an additional 12,235 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Akero Therapeutics by 31.2% in the first quarter. Envestnet Asset Management Inc. now owns 13,334 shares of the company’s stock valued at $540,000 after acquiring an additional 3,170 shares in the last quarter.

Insider Transactions at Akero Therapeutics

In related news, CFO William Richard White sold 659 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $43.02, for a total transaction of $28,350.18. Following the transaction, the chief financial officer directly owned 57,752 shares in the company, valued at $2,484,491.04. This trade represents a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jonathan Young sold 12,500 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $46.08, for a total value of $576,000.00. Following the transaction, the chief operating officer owned 197,484 shares in the company, valued at $9,100,062.72. This trade represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 156,753 shares of company stock valued at $7,456,064. Company insiders own 7.07% of the company’s stock.

Analyst Ratings Changes

AKRO has been the subject of several recent research reports. Canaccord Genuity Group downgraded shares of Akero Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $73.00 to $54.00 in a research report on Thursday, October 9th. Jefferies Financial Group downgraded shares of Akero Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $75.00 to $56.00 in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akero Therapeutics in a research report on Wednesday, October 8th. Wolfe Research downgraded shares of Akero Therapeutics from an “outperform” rating to a “hold” rating in a research report on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Akero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 11th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Hold” and an average target price of $73.38.

Akero Therapeutics Stock Down 0.1%

AKRO stock opened at $54.03 on Wednesday. Akero Therapeutics, Inc. has a twelve month low of $21.34 and a twelve month high of $58.40. The company has a current ratio of 12.66, a quick ratio of 12.66 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $4.32 billion, a P/E ratio of -27.02 and a beta of -0.35. The firm has a 50 day simple moving average of $48.81 and a 200-day simple moving average of $48.83.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.11. During the same quarter last year, the company posted ($0.81) EPS. On average, equities research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.